Learning outcomes
By the end of this lesson you should be able to: define heart failure in terms of cardiac output and filling pressures; distinguish reduced, mildly reduced and preserved ejection fraction and name the commonest cause of each; explain how the sympathetic, renin-angiotensin-aldosterone and natriuretic peptide responses compensate and then become harmful; separate the clinical picture of left-sided from right-sided failure; list the investigations that establish the diagnosis and its cause; and outline the four disease-modifying drug classes and the management of acute decompensation.
Prerequisites
PHYS 101 (the Frank-Starling mechanism, the determinants of cardiac output and the vasomotor reflexes), MED 301 lesson 2 (the vital signs and the interpretation of blood pressure), lesson 5 (the ECG), and the pathology of myocardial infarction and of hypertrophy from PATH 201.
The big idea
The definition is deliberately about function rather than about the ejection fraction, because a patient whose ventricle ejects a normal fraction may still be breathless and oedematous, and a patient with a badly damaged ventricle may have no symptoms yet. Two facts follow from the definition and drive everything else. First, the heart is a pump with a limited output, so when it fails the body defends the output rather than the filling pressure. Second, the defence — sympathetic activation and salt and water retention — improves output for days and then destroys the myocardium and floods the lungs over years. Heart failure is therefore a disease of compensation as much as of the muscle.
Heart failure is also a terminal common pathway rather than a single disease. It is what ischaemic heart disease, hypertension, valve disease, atrial fibrillation, alcohol, chemotherapy and cardiomyopathy all converge on, which is why establishing the cause is part of the diagnosis rather than an optional extra: the cause determines whether the failure is reversible and which additional treatment is indicated.
The phenotypes
| Phenotype | Ejection fraction | What is wrong | Commonest causes |
|---|---|---|---|
| Reduced (HFrEF) | Below 40 percent | The ventricle is dilated and weak: a systolic problem, in which the muscle cannot generate enough pressure to empty the chamber | Coronary disease and myocardial infarction, dilated cardiomyopathy, alcohol, valvular regurgitation, chemotherapy |
| Mildly reduced (HFmrEF) | 41 to 49 percent | A mixed systolic and filling problem, previously called mid-range failure | Coronary disease, hypertension, and the overlap of both mechanisms |
| Preserved (HFpEF) | 50 percent or more | The ventricle is stiff and cannot relax: a diastolic problem, in which filling requires a higher pressure | Hypertensive heart disease, ageing, diabetes, obesity, atrial fibrillation |
| High output | Preserved and often hyperdynamic | The pump is normal but the demand is excessive or the systemic resistance has fallen | Severe anaemia, thyrotoxicosis, arteriovenous fistula, Paget's disease, beriberi |
NoteThe distinction matters for treatment. The evidence that ACE inhibitors, beta-blockers, mineralocorticoid receptor antagonists and SGLT2 inhibitors save lives was established in reduced ejection fraction; in preserved ejection fraction only the SGLT2 inhibitors have proven benefit on top of treating the cause. Around half of all heart failure admissions are HFpEF, and they are the group in which the correct diagnosis is most often missed.
Preserved failure is worth understanding rather than merely labelling, because it explains the patient. The stiff ventricle empties normally, so resting cardiac output may be normal; but the ventricle cannot fill without an elevated atrial pressure, and that pressure is transmitted backwards into the lungs. Breathlessness is therefore produced by exertion (which shortens diastole) and by lying flat (which increases venous return), while the ejection fraction is measured as normal.
Compensation, and how it becomes the disease
| Mechanism | What it does at first | What it costs later |
|---|---|---|
| Sympathetic activation | Raises heart rate and contractility and constricts the arterioles, defending blood pressure and output | Increases myocardial oxygen demand, promotes arrhythmia, and down-regulates beta receptors so the failing heart becomes less responsive |
| Renin-angiotensin-aldosterone activation | Retains sodium and water, expanding preload and maintaining stroke volume by the Frank-Starling mechanism | Raises filling pressures into the lungs and periphery, causes vasoconstriction, and drives fibrosis and remodelling of the myocardium |
| Ventricular remodelling | The chamber dilates and hypertrophies, which raises wall stress and output | Wall stress is itself the signal for further remodelling, so the ventricle becomes progressively more dilated and less efficient |
| Natriuretic peptides | Released by the stretched atria and ventricles: promote sodium and water loss and oppose the renin system | Overwhelmed by the neurohormonal response, and degraded by neprilysin — which is why the peptides can be measured to make the diagnosis and protected by drugs to treat it |
This is the single most important idea in the subject, and it explains the paradox of therapy: every drug that most improves survival works by blocking a compensatory mechanism. Blocking the sympathetic drive, blocking angiotensin and aldosterone, and protecting the natriuretic peptides all worsen the measured ejection fraction for a few weeks while extending life for years.
Watch outA drug that improves symptoms may not improve survival, and a drug that improves survival may make the patient feel worse for a fortnight. Loop diuretics relieve congestion faster than anything else and have never been shown to prolong life; the four pillars below prolong life and may not make the patient feel better on the day they are started.
Left-sided and right-sided failure
| Left-sided failure | Right-sided failure | |
|---|---|---|
| Where pressure rises | Left atrium and pulmonary veins | Right atrium and systemic veins |
| Cardinal symptom | Breathlessness, worse on exertion and on lying flat, with waking at night gasping | Ankle swelling, abdominal bloating and early satiety, and fatigue |
| Positional feature | Orthopnoea (the number of pillows used to sleep) and paroxysmal nocturnal dyspnoea | Swelling that accumulates through the day and settles overnight |
| Examination | Bilateral basal crackles, a pleural effusion, a displaced apex beat, a third heart sound, tachypnoea | Raised jugular venous pressure with systolic v waves, pitting oedema, hepatomegaly, ascites, a raised venous pressure in the limbs |
| Associated findings | Nocturia, cough, frothy sputum in pulmonary oedema | Nausea, jaundice of congestion, weight gain from fluid |
| Commonest cause | Ischaemia, hypertension, aortic and mitral valve disease, atrial fibrillation | Left-sided failure; or intrinsic right disease — cor pulmonale from lung disease, pulmonary embolism, pulmonary hypertension, right infarction |
The two sides are commonly combined, because the failure of one raises the pressure on the other and because the causes overlap. What matters is that the dominant direction of congestion determines which symptom the patient reports. A patient who complains of swelling rather than of breath may still have a ventricle that ejects only 25 percent, and the temptation to treat the oedema as hepatic or venous disease is a real diagnostic trap.
Recognising it at the bedside
| Domain | What is assessed | Interpretation |
|---|---|---|
| Symptoms | Breathlessness at rest and on exertion, orthopnoea, paroxysmal nocturnal dyspnoea, fatigue, exercise intolerance | The symptoms are sensitive but not specific: they overlap with lung disease, obesity, anaemia and anxiety |
| Congestive signs | Raised jugular venous pressure, crackles at the bases, peripheral pitting oedema, weight gain of more than 2 kilograms in days | The combination of a raised venous pressure with either crackles or oedema is the most useful bedside pattern |
| Hypoperfusion | Cool peripheries, a narrow pulse pressure, confusion, oliguria, narrow pulse pressure with a raised venous pressure | Congestion plus hypoperfusion is the pattern of the lowest output and the highest acute risk |
| Daily weights and fluid balance | Weight measured each morning at the same time; a chart of intake and urine output | The earliest and most reliable detector of decompensation, and the number that guides diuretic titration at home |
Diagnosis, severity of function, and the cause
| Investigation | Finding | What it contributes |
|---|---|---|
| Natriuretic peptide (BNP or NT-proBNP) | A level below the rule-out threshold (BNP under 100, NT-proBNP under 300 nanograms per litre) makes untreated heart failure very unlikely; a very high level makes it very likely | The best single test for excluding the diagnosis in a breathless patient, and the best prognostic marker |
| Echocardiography | Ejection fraction, chamber size, wall thickness, valve function, regional wall motion, diastolic filling | The investigation that classifies the phenotype and identifies a treatable cause such as valve disease |
| Chest radiograph | Cardiomegaly, upper-lobe diversion, Kerley B lines, pleural effusions, alveolar shadowing | Distinguishes pulmonary oedema from pneumonia and hyperinflation in a breathless patient |
| Electrocardiogram | Q waves, left ventricular hypertrophy, atrial fibrillation, bundle branch block, broad complexes | A completely normal ECG makes a reduced ejection fraction unlikely and points towards a preserved phenotype |
| Bloods | Renal function, electrolytes, haemoglobin, thyroid function, ferritin and transferrin saturation, glucose and lipids | Detects a precipitant (anaemia, renal impairment), a cause (thyroid disease, iron deficiency) and guides safe titration |
| Further testing | Coronary angiography or CT angiography, cardiac MRI, an exercise test, a myocardial biopsy in selected cases | Establishes the aetiology — ischaemia, infiltrative disease, inflammation, or cardiomyopathy |
NoteNatriuretic peptides are raised by age, renal impairment and atrial fibrillation, and are lowered by obesity — so an intermediate result in a patient with more than one of these is interpreted against the clinical picture rather than on its own.
The NYHA functional classification
| Class | Limitation | Typical activity |
|---|---|---|
| I | No limitation of ordinary physical activity | Climbs stairs and walks on the flat without symptoms |
| II | Slight limitation: comfortable at rest, symptomatic on ordinary exertion | Breathless climbing one flight of stairs or walking uphill |
| III | Marked limitation: comfortable at rest, symptomatic on less than ordinary exertion | Breathless walking on the flat or dressing |
| IV | Unable to carry out any activity without symptoms, or symptomatic at rest | Breathless sitting in a chair |
Treatment: the four pillars
| Class | Examples | What it does | Cautions |
|---|---|---|---|
| Angiotensin receptor neprilysin inhibitor, or an ACE inhibitor or an angiotensin receptor blocker | Sacubitril-valsartan, enalapril or ramipril, losartan or valsartan | Reduces preload and afterload, blocks the maladaptive neurohormonal response and reduces mortality and hospitalisation | Monitor renal function and potassium, start low and titrate; a cough on an ACE inhibitor (bradykinin) prompts a switch to an angiotensin blocker; a rise in creatinine of more than 30 percent prompts review |
| Beta-blocker | Bisoprolol, carvedilol, metoprolol succinate (nebivolol where carvedilol is not tolerated) | Blocks the sympathetic drive, improves ejection fraction, reduces sudden death and mortality | Only three agents have evidence; start low and double at intervals of at least two weeks once the patient is stable; do not start while the patient is congested or decompensated; a transient worsening of symptoms is common |
| Mineralocorticoid receptor antagonist | Spironolactone, eplerenone | Blocks aldosterone, prevents fibrosis, reduces mortality in symptomatic reduced failure and in post-infarction failure | Monitor potassium and renal function; gynaecomastia with spironolactone; avoid in renal impairment with a rising potassium |
| SGLT2 inhibitor | Dapagliflozin, empagliflozin | Originally glucose-lowering drugs: reduce hospitalisation and mortality in reduced and in preserved failure, and also slow renal decline | Genital and urinary infections, euglycaemic ketoacidosis rarely, and a small initial diuresis; benefit within weeks and independent of diabetes status |
The four classes are complementary rather than alternatives, and the target is all four unless one is contraindicated or not tolerated. Therapy is titrated: a low starting dose, then reassessment of renal function, potassium, blood pressure and symptoms within one to two weeks, and then a step upward. Devices sit alongside: an implantable defibrillator in a ventricular ejection fraction below 35 percent despite optimal medical therapy, and cardiac resynchronisation therapy when the QRS is broad with left bundle branch block morphology.
Loop diuretics — furosemide, bumetanide, torsemide — are the congestion drugs, and are adjusted to the patient's weight and fluid balance rather than to a fixed dose. Digoxin has a narrow role: it reduces hospitalisation in patients who remain symptomatic despite other therapy, particularly with atrial fibrillation. Ivabradine slows the sinus rate and helps patients in sinus rhythm with a heart rate above 70 who cannot take a beta-blocker.
Watch outDo not start a beta-blocker during acute decompensation, and do not stop it reflexively on admission unless the patient is shocked or inotrope-dependent. Withdrawal of chronic beta-blocker therapy in the acutely decompensated patient is associated with worse survival, so the dose is reduced or continued rather than stopped.
Acute decompensated heart failure
| Picture | Physiology | Acute management |
|---|---|---|
| Warm and wet (most common) | Congested with an adequate blood pressure — pulmonary oedema and peripheral oedema with preserved perfusion | Intravenous loop diuretic, oxygen for hypoxaemia, vasodilator to reduce preload, and treatment of the precipitant |
| Cold and wet (worst prognosis) | Congested and hypoperfused — cool peripheries, oliguria, confusion, narrowed pulse pressure | Inotropic support, urgent review for mechanical support, and intensive care referral; diuresis alone will not rescue a failing perfusion |
| Warm and dry | Compensated failure on treatment | Continue and optimise the oral regimen, treat the precipitant, and arrange follow-up |
| Cold and dry | Low output without congestion, usually from over-diuresis | Careful fluid replacement and review of the diuretic dose before escalating inotropes |
The precipitant is found in almost every admission and is often more urgent than the failure itself: infection, myocardial infarction, arrhythmia (particularly atrial fibrillation with a fast rate), anaemia, thyroid disease, renal impairment, a missed dose or a dietary salt and water load, a new drug (a non-steroidal anti-inflammatory, a thiazolidinedione, a negative inotrope), and pregnancy.
NoteNon-invasive ventilation is reserved for respiratory failure that persists despite medical therapy in cardiogenic pulmonary oedema: it improves oxygenation and reduces the work of breathing while the diuresis takes effect, and reduces the need for intubation in the sickest patients.
Common mistakes
Watch outDiagnosing chronic lung disease in a patient with breathlessness because the lungs are the obvious focus. Heart failure presents with exactly the same symptom, so a raised jugular venous pressure, displaced apex beat and natriuretic peptide are checked in every breathless patient.
Watch outTreating a normal ejection fraction as excluding heart failure. Preserved failure is diagnosed on the combination of symptoms, raised filling pressures and a normal ejection fraction, and it is the commonest presentation in elderly women and in hypertensive patients.
Watch outTitrating diuretics alone. Diuretics are essential for congestion but do not modify the disease: a patient admitted repeatedly with congestion who is not on an angiotensin blocker, a beta-blocker, a mineralocorticoid receptor antagonist and an SGLT2 inhibitor has not received disease-modifying treatment.
Watch outPrescribing a non-steroidal anti-inflammatory drug to a patient with heart failure. These drugs cause sodium retention, blunt diuretic response and worsen renal function, and are among the commonest precipitating drugs in an admission.
Check your understanding
Why do the drugs that prolong life in heart failure initially make some patients feel worse, and how does that fit with the definition of the syndrome?
A patient reports breathlessness on climbing one flight of stairs and sleeping on two pillows rather than one. Which features of heart failure are described, and what would you expect to find on examination?
How is acute decompensated heart failure classified at the bedside, and why does the classification matter?
Multiple choice
A patient with an ejection fraction of 28 percent is admitted with pulmonary oedema. Which class of drug has the strongest evidence for reducing mortality in this patient?
Which finding is most characteristic of heart failure with preserved ejection fraction?
A patient with chronic heart failure on full oral therapy is admitted with a weight gain of 4 kilograms, pulmonary crackles and cool peripheries. What does the cold, wet profile indicate?
Which investigation is the most useful for excluding heart failure in a patient with undifferentiated breathlessness?
A patient admitted with decompensated heart failure has been taking bisoprolol for two years and is not shocked. What is the correct management of the beta-blocker?
Module summary and next
Heart failure is the terminal common pathway of cardiac disease, and its teaching divides cleanly into three parts: the phenotype (what the ejection fraction is doing), the congestion (where the fluid is accumulating and how to remove it) and the neurohormonal response (which the four disease-modifying drug classes exist to block). The same patient will be described in all three languages, and keeping them separate keeps the treatment rational.
Next: ischaemic heart disease, which is the commonest single cause of the syndrome you have just studied, and the acute coronary syndromes, which are its commonest precipitant.